Kymera Therapeutics Present’s Clinical Data From The Ongoing Phase 1 Trial Of STAT3 Degrader KT-333 At EHA Annual Meeting June 13-16, 2024, In Madrid, Spain
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual